Bednarek M A, MacNeil T, Kalyani R N, Tang R, Van der Ploeg L H, Weinberg D H
Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065, USA.
Biochem Biophys Res Commun. 2000 May 27;272(1):23-8. doi: 10.1006/bbrc.2000.2589.
A role of the aromatic and of the basic residues of the potent agonist (MTII) and antagonist (SHU9119) at the human melanocortin receptors 4 in the formation and stabilization of ligand-receptor complexes was examined. Analogs of MTII and SHU9119 with glutamic acid replacing one amino acid at a time were synthesized and tested for their ability to bind to and activate human melanocortin receptors 3, 4, and 5. Replacement of Phe (Nal) or Trp with Glu resulted in analogs of MTII and SHU9119 which were practically inactive at the receptors studied. The rather large (and unexpected) tolerance toward the presence of Glu in the position of His or Arg of MTII and SHU9119 clearly suggested that in the ligand receptor complexes these basic residues are not in contact with the receptors but probably face the extracellular environment. This identified the aromatic residues of MTII and SHU9119 as the primary structural features determining interactions of the agonist/antagonist with hMCR3-5.
研究了强效激动剂(MTII)和拮抗剂(SHU9119)的芳香族和碱性残基在人黑皮质素受体4配体-受体复合物形成和稳定中的作用。合成了MTII和SHU9119的类似物,每次用谷氨酸取代一个氨基酸,并测试它们与人类黑皮质素受体3、4和5结合及激活的能力。用谷氨酸取代苯丙氨酸(Nal)或色氨酸后得到的MTII和SHU9119类似物在所研究的受体上几乎没有活性。MTII和SHU9119的组氨酸或精氨酸位置对谷氨酸的存在具有相当大(且出乎意料)的耐受性,这清楚地表明在配体-受体复合物中,这些碱性残基不与受体接触,而是可能面向细胞外环境。这确定了MTII和SHU9119的芳香族残基是决定激动剂/拮抗剂与hMCR3-5相互作用的主要结构特征。